Milestones in camptothecin research

Drugs of the Future

Volumn 27, Issue 9, 2002, Pages 869-878

  Lerchen, Hans Georg ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFELETECAN; BELOTECAN; CAMPTOTESIN; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; DE 310; DIFLOMOTECAN; DOXORUBICIN; ETOPOSIDE; EXATECAN; GIMATECAN; IRINOTECAN; KARENITECIN; LURTOTECAN; PROTHECAN; RUBITECAN; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ISOLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; LEUKEMIA; LUNG SMALL CELL CANCER; NONHUMAN; REVIEW; SOLID TUMOR;

EID: 0036759731     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.09.694498     Document Type: Review

References (81)

1. Wall, M.E., Wani, M.C., Cook, C.E., Palmer, K.H., McPhail, A.T., Sim, G. A. Plant antitumor agents. I/. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966, 88: 3888-90.
2. Gottlieb, J.A., Guarino, A.M., Call, J.B., Oliverio, V.T., Block, J.B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 1970, 54: 461-79.
3. Muggia, F.M., Creaven, P.J., Jansen, H.H., Cohen, M.N., Selawry, D.S. Phase I clinical trials of weekly and daily treatment with camptothecin (NSC 100880). Correlation with clinical studies. Cancer Chemother Rep 1972, 56: 515-21.
4. Moertel, C.G., Schutt, A.J., Reitemeier, R.J., Hahn, R.G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972, 56: 95-101.
5. Stork, G., Schultz, A.G. The total synthesis of dl-camptothecin. J Am Chem Soc 1971, 93: 4074-5.
6. Wani, M.C., Campbell, H.F., Brine, G.A., Kepler, J.A., Wall, M.E., Levine, S.G. Plant antitumor agents. IX. The total synthesis of dl-camptothecin. J Am Chem Soc 1972, 94: 3631-2.
7. Zhou, Y., You, Q., Li, Y., Zhou, H. Synthesis of camptothecin derivatives. Zhongguo Yiyao Gongye Zazhi 2001, 32: 375-80.
8. Baurle, S., Koert, U. Camptothecin - Synthesis of an antitumor agent. In: Organic Synthesis Highlights IV. H.G. Schmalz (Ed.). Wiley-VCH Verlag: Weinheim 2000, 232-40.
9. Jew, S.S., Kim, M.G., Kim, H.J., Roh, E.Y., Park, H.G. Synthesis and antitumor activity of camptothecin analogues. Kor J Med Chem 1996, 6: 263-82.
10. Wall, M.E., Wani, L.C. Antineoplastic agents from plants. Ann Rev Pharmacol Toxicol 1977, 17: 117-32.
11. Wani, M.C., Ronman, P.E., Lindley, J.T., Wall, M.E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem 1980, 23: 554-60.
12. Kehrer, D.F.S., Soepenberg, O., Loos, W.J., Verweij, J., Sparreboom, A. Modulation of camptothecin analogs in the treatment of cancer: A review. Anti-Cancer Drugs 2001, 12: 89-105.
13. Wani, M.C., Nicholas, A.W., Wall, M.E. Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues. J Med Chem 1986, 29: 2358-63.
14. Verschraegen, C.F. RFS-2000. Stehlin Foundation for Cancer Research. Curr Opin Oncol Endocr Metab Invest Drugs 1999, 1: 184-90.
15. Pantazis, P., Early, J.A., Kozielski, A.J., Mendoza, J.T., Hinz, H.R., Giovanella, B.C. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: Differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Research 1993, 53: 1577-82.
16. Pantazis, P., Han, Z., Chatterjee, D., Wyche, J.H. 9-Nitrocamptothecin: Antineoplastic antiviral DNA topoisomerase I inhibitor. Drugs Fut 1999, 24: 1311-23.
17. Natelson, E.A., Giovanella, B.C., Verschraegen, C.F. et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 1996, 803: 224-30.
18. Hsiang, Y.H., Hertzberg, R., Hecht, S., Liu, L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase. J Biol Chem 1985, 260: 14873-8.
19. Jaxel, C., Kohn, K.W., Wani, M.C., Wall, M.E. Structure activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res 1989, 49: 1465-9.
20. Hsiang, Y.H., Liu, L.F., Wall, M.E. et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 1989, 49: 4385-9.
21. Redinbo, M.R., Stewart, L., Kuhn, P., Champoux, J.J., Hol, W.G.J. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998, 279: 1504-13.
22. Fan, Y., Weinstein, J.N., Kohn, K.W., Shi, L.M., Pommier, Y. Molecular modeling studies of the DNA-topoisomerase I ternary tematy cleavable complex with camptothecin. J Med Chem 1998, 41: 2216-26.
23. Kerrigan, J.E., Pilch, D.S. A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin. Biochemistry 2001, 40: 9792-8.
24. Laco, G.S., Collins, J.R., Luke, B.T. et al. Human topoisomerase I inhibition: Docking camptothecin and derivatives into a structure-based active site model. Biochemistry 2002, 41: 1428-35.
25. Houghton, P.J., Stewart, C.F., Zamboni, W.C. et al. Schedule-dependent efficacy of camptothecins in models of human cancer. Ann NY Acad Sci 1996, 803: 188-201.
26. Hertzberg, R.P., Caranfa, M.J., Holden, K.G. et al. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989, 32: 715-20.
27. Fassberg, J., Stella, V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992, 120: 2979-80.
28. Burke, T.G., Mi, Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 1993, 212: 285-7.
29. Burke, T.G. Chemistry of the camptothecins in the bloodstream: Drug stabilization and optimization of activity. Ann NY Acad Sci 1996, 803: 29-31.
30. Zufia, L., Aldaz, A., Giraldez, J. Separation methods for camptothecin and related compounds. J Chromatogr B Biomed Sci Appl 2001, 764: 141-59.
31. Oguma, T. Antitumor drugs possessing topoisomerase I inhibition: Applicable separation methods. J Chromatogr B Biomed Sci Appl 2001, 764: 49-58.
32. Palumbo, M., Sissi, C., Gatto, B., Moro, S., Zagotto, G. Quantitation of camptothecin and related compounds. J Chromatogr B Biomed Sci Appl 2001, 764: 121-40.
33. Mathijssen, R.H.J., Van Alphen, R.J., Verweij, J. et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001, 7: 2182-94.
34. Sawada, S., Okajima, S., Aiyama, R. et al. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: Carbamatelinked, water soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull 1991, 39: 1446-54.
35. Kaneda, N., Hosokawa, Y., Yokokura, T., Awazu, S. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats. Biol Pharm Bull 1997, 20: 992-6.
36. Humerickhouse, R., Lohrbach, K., Li, L., Bosron, W.F., Dolan, M.E. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-0 and hCE-2. Cancer Res 2000, 60: 1189-92.
37. Lavelle, F., Bissery, M.-C., Andre, S., Roquet, F., Riou, J.-F. Preclinical evaluation of CPT-II and its active metabolite SN-38. Semin Oncol 1996, 23: 11-20.
38. Takasuna, K., Hagiwara, T., Hirohashi, M. et al. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 1998, 42: 280-6.
39. Rivory, L.P., Bowles, M.R., Robert, J., Pond, S.M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 1996, 52: 1103-11.
40. Saleem, A., Edwards, T.K., Rasheed, Z., Rubin, E.H. Mechanisms of resistance to camptothecins. Ann NY Acad Sci 2000, 922: 46-55.
41. Rothenberg, M.L. Irinotecan (CPT-11): Recent developments and future directions - Colorectal cancer and beyond. Oncologist 2001, 6: 66-80.
42. 14C]CPT-11 in cancer patients. Drug Metab Dispos 2000, 28: 423-33.
43. Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., Rustum, Y.M. Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 2001, 19: 1501-18.
44. Cunningham, D., Maroun, J., Vanhoefer, U., Van Cutsem, E. Optimizing the use of irinotecan in colorectal cancer. Oncologist 2001, 6: 17-23.
45. Kingsbury, W.D., Boehm, J.C., Jakas, D.R. et al. Synthesis of water-soluble (aminoalky)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 1991, 34: 98-107.
46. Kollmannsberger, C., Mross, K., Jakob, A., Kanz, L., Bokemeyer, C. Topotecan, a novel topoisomerase I inhibitor. Pharmacology and clinical experience. Oncology 1999, 56: 1-12.
47. Carmichael, J., Ozols, R.F. Topotecan, an active new antineoplastic agent: Review and current status. Exp Opin Invest Drugs 1997, 6: 593-608.
48. Bolis, G., Malmstrom, H., Coleman, R. et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997, 15: 2183-93.
49. Ormrod, D., Spencer, C.M. Topotecan: A review of its efficacy in small-cell lung cancer. Drugs 1999, 58: 533-51.
50. Burris, H.A. III. The evolving role of oral topotecan. Semin Hematol 1999, 36: 26-32.
51. Rowinsky, E.K., Kaufmann, S.H. Topotecan in combination chemotherapy. Semin Oncol 1997, 24: S20-11-S20-26.
52. Mitsui, I., Kumazawa, E., Hirota, Y. et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995, 86: 776-82.
53. Kumazawa, E., Jimbo, T., Ochi, Y., Tohgo, A. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Pharmacol 1998, 42: 210-20.
54. De Jager, R., Cheverton, P., Tamanoi, K. et al. DX-8951f: Summary of phase I clinical trials. Ann NY Acad Sci 2000, 922: 260-73.
55. Verschraegen, C.F., Royce, M., Hammond, L., Rowinsky, E.K. Exatecan, Daiichi Seiyaku Co Ltd. Curr Opin Oncol Endocr Metab Invest Drugs 2000, 2: 312-19.
56. Emerson, D.L., Besterman, J.M., Brown, H.R. et al. In vivo antitumor activity of two seven-substituted water-soluble camptothecin analogues. Cancer Res 1995, 55: 603-9.
57. Emerson, D.L. Liposomal delivery of camptothecins. Pharm Sci Technol Today 2000, 3: 205-9.
58. Emerson, D.L., Bendele, R., Brown, E. et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A lowclearance liposomal formulation of lurtotecan. Clin Cancer Res 2000, 6: 2903-12.
59. Lee, J.H., Sohn, Y.S., Lee, J.M. et al. Antitumor activities of CKD602, a novel camptothecin derivative. Proc Am Assoc Cancer Res 1998, 39: Abst 2071.
60. Ahn, S.K., Kim, J.K., Hong, C.I. Oncolytic DNA topoisomerase I inhibitor, CKD-602. Drugs Fut 2000, 25: 1243-6.
61. Lee, J.H., Lee, J.M., Lim, K.H. et al. Preclinical and phase I clinical studies with CKD-602, a novel camptothecin derivative. Ann NY Acad Sci 2000, 922: 324-5.
62. Bom, D., Curran, D.P., Kruszewski, S. et al. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 2000, 43: 3970-80.
63. Van Hattum, A.H., Pinedo, H.M., Schluper, H.M.M., Hausheer, F.H., Boven, E. New highly lipophilic captothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer 2000, 88: 260-6.
64. Dallavalle, S., Delsoldato, T., Ferrari, A. et al. Novel 7-substituted camptothecins with potent antitumor activity. J Med Chem 2000, 43: 3963-9.
65. De Cesare, M., Pratesi, G., Perego, P. et al. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 2001, 61: 7189-95.
66. Lavergne, O., Lesueur-Ginot, L., Rodas, F.P., Bigg, D.C.H. BN 80245: An E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg Med Chem Lett 1997, 7: 2235-8.
67. Bom, D., Curran, D.P., Chavan, A.Y. et al. Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. J Med Chem 1999, 42: 3018-22.
68. Demarquay, D., Huchet, M., Coulomb, H. et al. The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison. Anti-Cancer Drugs 2001, 12: 9-19.
69. Lavergne, O., Lesueur-Ginot, L., Rodas, F.P. et al. Homocamptothecins: Synthesis and antitumor activity of novel E-ring-modified camptothecin analogs. J Med Chem 1998, 41: 5410-9.
70. Cao, C., Harris, N., Kozielski, A., Vardeman, D., Stehlin, J.S., Giovanella, B. Alkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis, in vitro pharmacokinetics, toxicity and antitumor activity. J Med Chem 1998, 41: 31-7.
71. Lerchen, H.-G., Von Dem Bruch, K. Synthesis of 20-C-linked 20(S)-camptothecin glycoconjugates: Impact of the side chain of the ester-linked amino acid on epimerization during the acylation reaction and on hydrolytic stability of the final glycoconjugates. J Prakt Chem 2000, 342: 753-60.
72. Singer, J.W., De Vries, P., Bhatt, R. et al. Conjugation of camptothecins to poly(L-glutamic acid). Ann NY Acad Sci 2000, 922: 136-50.
73. Conover, C.D., Pendri, A., Lee, C., Gilbert, C.W., Shum, K.L., Greenwald, R.B. Camptothecin delivery systems: The antitumor activity of a camptothecin-20-O-polyethylene glycol ester transport form. Anticancer Res 1997, 17: 3361-8.
74. Maeda, H., Matsumura, Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Systems 1989, 6: 193-210.
75. Lerchen, H.-G., Baumgarten, J., von Bruch, K. et al. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. J Med Chem 2001, 44: 4186-95.
76. Masubuchi, N., Gohda, R., Seki, H., Hayashi, K., Atsumi, R., Inoue, K. DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f (III): Pharmacokinetic evaluation in normal and tumor-bearing mice. Proc Am Ass Cancer Res 2001, 42: Abst 2025.
77. Ochi, Y., Kumazawa, E., Nakata, M., Tanaka, N., Inoue, K. DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f (II): Its antitumor activities in several model systems of human and murine tumors. Proc Am Ass Cancer Res 2001, 42: Abst 748.
78. Harada, M., Sakakibara, H., Yano, T., Suzuki, T., Okuno, S. Determinants for the drug release from T-0128, camptothecin analog-carboxymethyl dextran conjugate. J Control Rel 2000, 69: 399-412.
79. Greenwald, R.B., Pendri, A., Conover, C., Gilbert, C., Yang, R., Xia, J. Drug delivery systems. 2. Camptothecin 20-O-polyethylene glycol ester transport forms. J Med Chem 1996, 39: 1938-40.
80. Greenwald, R.B., Pendri, A., Conover, C.D. et al. Camptothecin-20-PEG ester transport forms: The effect of spacer groups on antitumor activity. Bioorg Med Chem 1998, 6: 551-62.
81. Singer, J.W., Bhatt, R., Tulinsky, J. et al. Water-soluble poly(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J Control Rel 2001, 74: 243-7.